The global cognitive impairment associated with schizophrenia (CIAS) market is primarily driven by the rising prevalence of schizophrenia across the globe. The CIAS refers to impairment in cognitive domains including working memory, verbal learning, attention, and problem solving associated with schizophrenia. Patients suffering from schizophrenia often exhibit cognitive dysfunctions even during clinically stable phases which severely impacts their social and occupational functioning.
The Global Cognitive Impairment Associated With Schizophrenia (CIAS) Market is estimated to be valued at USD 5.2 Bn in 2024 and is expected to reach USD 7.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031.
Treatment options available for managing Cognitive Impairment Associated With Schizophrenia (CIAS) Market includes atypical and typical antipsychotics, cognitive enhancers such as donepezil, rivastigmine, galantamine, memantine, cognitive training & rehabilitation, and other adjunctive therapies.
Key players operating in the CIAS market are Otsuka Pharmaceutical Co., Ltd., Allergan plc, Alkermes plc, Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd, Bristol-Myers Squibb, and Johnson & Johnson.
The key opportunities in the CIAS market include development of novel drugs targeting cognitive dysfunctions, integration of digital technologies in cognitive assessments and training, and lack of effective treatment options indicating high unmet needs. The global players are focused on expanding their geographic presence in emerging markets of Asia Pacific, Latin America, and Middle East & Africa owing to larger patient pools and growing healthcare expenditures in these regions.
Market Drivers
- Increasing approval and launch of new drugs: Drugs such as Ingrezza, Axura, and Caplyta have been approved in recent years expanding the treatment options.
- Rising awareness initiatives by governments and healthcare organizations: Various programs aim to reduce stigma and enhance early diagnosis and management of schizophrenia.
Market Restraints
- High cost of treatment: Drugs for managing cognitive symptoms are expensive and impose significant burden on payers.
- Poor adherence to medications: Non-adherence to oral antipsychotics is common due to poor efficacy, tolerability issues, and complex dosing schedules.
Segment Analysis
The global cognitive impairment associated with schizophrenia (CIAS) market is segmented into drug class, distribution channel, and region. Based on drug class, the market is divided into second-generation antipsychotics, third-generation antipsychotics, and others. Among these, the third-generation antipsychotics segment dominated in 2022 owing to fewer side effects and improved efficacy in treating both positive and negative symptoms of schizophrenia than previous antipsychotics. In terms of distribution channel, the market is bifurcated into hospitals pharmacies, retail pharmacies, and online pharmacies. The hospitals pharmacies segment accounted for the largest share of the market due to higher patient volume and ease of procurement of drugs via hospitals.
Global Analysis
Regionally, North America held the largest share of the global cognitive impairment associated with schizophrenia market in 2022 followed by Europe. This is attributed to factors such as well-developed healthcare infrastructure, high awareness regarding schizophrenia treatment, and new drug approvals. Asia Pacific is expected to witness the highest CAGR over the forecast period owing to the increasing patient pool, growing healthcare expenditure, and expanding healthcare sector in emerging economies like India and China. Whereas, Latin America and Middle East & Africa are anticipated to offer lucrative growth opportunities during the forecast period owing to improving medical facilities and rising adoption of schizophrenia treatment drugs.
Get this Report in Japanese Language: 統合失調症に伴う認知障害（CIAS）市場
Get this Report in Korean Language: 정신분열증과 관련된 인지 장애(CIAS) 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Another study, titled , offers a survey of experts and the scope of momentum and future assessments in and out of the market, product specifications, showcase pattern entry type focus points, and written surveys.
Facts and numbers, a portion of the import industry as a whole made from this report offering, and the rate of development of each type and application, gross profit, and key variables heading into the market.
Quality, Weaknesses, Opportunities, Threats to Business, etc.The report registers the intrinsic subtleties of the industry, mainly relying on the basic diagram of the market chain structure of cognitive impairment testing tools, and the development of the market through the upstream and downstream industry environment, making the industry-wide speculative investigation cost structure the main strategy, planning, improvement of the industry Players logically anticipate the prospects of improvement business based on historical, present and presumptive information specified in the Cognitive Disability Screening Tool touted from 2019 to 2025 by driving key business decisions.Request a sample copy of this report at the following URL:https://www.researchforetell.com/reports/114721/cognitive-impairment-screening-tools-market—global-outlook-and-forecast-2021-2027 / requestDirectly adjacent to the global Cognitive Impairment Testing Tools Market is a market review, upstream, technology, and cost structure drawn.
The following part presents a showcase of the global Cognitive Impairment Testing Tools by key players, by application and type.
Likewise, it includes an examination of the competitive structure of the Cognitive Impairment Testing Tools industry by market income, trading, and Cognitive Impairment Testing Tools marketed by prominent key players in the region.
Finally, it features of the Cognitive Impairment Testing Tools market investment market,Segmentation of Global Cognitive Impairment Testing Tools Market:2020 (%) by type children adult 2020 (%) by application Medical and Life Sciences cultivate Enterprise Additionally, the report presents the profile of market competition as follows: Pie Recognition saber motivated mind mcquaig Mettoru test dome hacker rank e skill standard construction Coordination athena exponent execution Is it Cambridge?
Some important supplements are essential for the brain to function.
You have to provide your mind with these supplements so that you won't fall prey for cognitive decline as you age.The two best supplements that will keep you going is Vitamin D and Omega-3 fatty acids.
The test has been conducted for more than 4,500 people, and it has been proven that people with very low Vitamin D level are suffering from cognitive impairment.Depression is another decisive mental health battle that most of the people are fighting with these days irrespective of their age.
The increase of Vitamin D in blood level will surely create an impact on the depression too.
Research has proven that for every ten units of more Vitamin D in the blood, there is eight percent less chance of getting depression.Vitamin D plays a very crucial role when it comes to the improvement of brain health.
It is essential for you to provide your body with enough Vitamin D supplement so that your brain works more actively and do not get depressed at times.Omega-3 Fatty AcidsMost of the people do not get enough Omega-3 from their diet but this Omega-3 impacts the brain health a lot.
